These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

718 related items for PubMed ID: 20720518

  • 1. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease.
    de Winter BC, Mathot RA, Sombogaard F, Neumann I, van Hest RM, Doorduijn JK, van Gelder T.
    Ther Drug Monit; 2010 Oct; 32(5):606-14. PubMed ID: 20720518
    [Abstract] [Full Text] [Related]

  • 2. Population pharmacokinetics of mycophenolic acid in renal transplant recipients.
    van Hest RM, van Gelder T, Vulto AG, Mathot RA.
    Clin Pharmacokinet; 2005 Oct; 44(10):1083-96. PubMed ID: 16176120
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.
    de Winter BC, van Gelder T, Sombogaard F, Shaw LM, van Hest RM, Mathot RA.
    J Pharmacokinet Pharmacodyn; 2009 Dec; 36(6):541-64. PubMed ID: 19904584
    [Abstract] [Full Text] [Related]

  • 4. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B.
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [Abstract] [Full Text] [Related]

  • 5. Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients.
    de Winter BC, van Gelder T, Glander P, Cattaneo D, Tedesco-Silva H, Neumann I, Hilbrands L, van Hest RM, Pescovitz MD, Budde K, Mathot RA.
    Clin Pharmacokinet; 2008 Feb; 47(12):827-38. PubMed ID: 19026038
    [Abstract] [Full Text] [Related]

  • 6. Atypical pharmacokinetics and metabolism of mycophenolic acid in a young kidney transplant recipient with impaired renal function.
    Wigger M, Armstrong VW, Shipkova M, Wacke R, Nizze H, Streit F, von Ahsen N, Muscheites J, Glasenapp S, Stolpe HJ, Oellerich M.
    Ther Drug Monit; 2002 Jun; 24(3):438-43. PubMed ID: 12021639
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine.
    Lobritto SJ, Rosenthal P, Bouw R, Leung M, Snell P, Mamelok RD.
    Liver Transpl; 2007 Nov; 13(11):1570-5. PubMed ID: 17969194
    [Abstract] [Full Text] [Related]

  • 8. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings.
    Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, Esquenazi V, Burke G, Tzakis A, Miller J.
    Transpl Immunol; 1997 Sep; 5(3):225-32. PubMed ID: 9402690
    [Abstract] [Full Text] [Related]

  • 9. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.
    Mardigyan V, Tchervenkov J, Metrakos P, Barkun J, Deschenes M, Cantarovich M.
    Clin Ther; 2005 Apr; 27(4):463-9. PubMed ID: 15922819
    [Abstract] [Full Text] [Related]

  • 10. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range.
    Tredger JM, Brown NW, Adams J, Gonde CE, Dhawan A, Rela M, Heaton N.
    Liver Transpl; 2004 Apr; 10(4):492-502. PubMed ID: 15048791
    [Abstract] [Full Text] [Related]

  • 11. Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil.
    Dipchand AI, Pietra B, McCrindle BW, Rosebrook-Bicknell HL, Boucek MM.
    J Heart Lung Transplant; 2001 Oct; 20(10):1035-43. PubMed ID: 11595558
    [Abstract] [Full Text] [Related]

  • 12. Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil.
    Li H, Mager DE, Sandmaier BM, Maloney DG, Bemer MJ, McCune JS.
    J Clin Pharmacol; 2013 Apr; 53(4):393-402. PubMed ID: 23382105
    [Abstract] [Full Text] [Related]

  • 13. Renal graft function and low-dose cyclosporine affect mycophenolic acid pharmacokinetics in kidney transplantation.
    Cortinovis M, Gotti E, Pradini S, Gaspari F, Perico N.
    Transplantation; 2011 Sep 15; 92(5):550-6. PubMed ID: 21709602
    [Abstract] [Full Text] [Related]

  • 14. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation.
    Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Suzuki T, Habuchi T.
    Ther Drug Monit; 2008 Feb 15; 30(1):46-51. PubMed ID: 18223462
    [Abstract] [Full Text] [Related]

  • 15. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.
    Cremers S, Schoemaker R, Scholten E, den Hartigh J, König-Quartel J, van Kan E, Paul L, de Fijter J.
    Br J Clin Pharmacol; 2005 Sep 15; 60(3):249-56. PubMed ID: 16120063
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics of mycophenolate mofetil in hematopoietic stem cell transplant recipients.
    van Hest RM, Doorduijn JK, de Winter BC, Cornelissen JJ, Vulto AG, Oellerich M, Löwenberg B, Mathot RA, Armstrong VW, van Gelder T.
    Ther Drug Monit; 2007 Jun 15; 29(3):353-60. PubMed ID: 17529894
    [Abstract] [Full Text] [Related]

  • 17. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
    Tett SE, Saint-Marcoux F, Staatz CE, Brunet M, Vinks AA, Miura M, Marquet P, Kuypers DR, van Gelder T, Cattaneo D.
    Transplant Rev (Orlando); 2011 Apr 15; 25(2):47-57. PubMed ID: 21190834
    [Abstract] [Full Text] [Related]

  • 18. Time-dependent clearance of mycophenolic acid in renal transplant recipients.
    van Hest RM, van Gelder T, Bouw R, Goggin T, Gordon R, Mamelok RD, Mathot RA.
    Br J Clin Pharmacol; 2007 Jun 15; 63(6):741-52. PubMed ID: 17214827
    [Abstract] [Full Text] [Related]

  • 19. Population pharmacokinetic analysis of mycophenolic acid coadministered with either tasocitinib (CP-690,550) or tacrolimus in adult renal allograft recipients.
    Lamba M, Tafti B, Melcher M, Chan G, Krishnaswami S, Busque S.
    Ther Drug Monit; 2010 Dec 15; 32(6):778-81. PubMed ID: 20926996
    [Abstract] [Full Text] [Related]

  • 20. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy.
    Grinyó JM, Ekberg H, Mamelok RD, Oppenheimer F, Sánchez-Plumed J, Gentil MA, Hernandez D, Kuypers DR, Brunet M.
    Nephrol Dial Transplant; 2009 Jul 15; 24(7):2269-76. PubMed ID: 19357111
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.